Author: Ravi Shankar

GADSDEN, Ala., Nov. 12, 2026 (GLOBE NEWSWIRE) — The Southern Banc Company, Inc. (OTCID: SRNN) (“the Company”), the holding company for The Southern Bank Company (“the Bank”), formerly First Federal Savings and Loan Association of Gadsden, Alabama, announced net income of approximately $762,000, or $1.00 per basic and $0.99 per diluted share, for the quarter ended September 30, 2026, compared to a net income of approximately $188,000, or $0.25 per basic and diluted share, for the quarter ended September 30, 2025.

Gates Little, President and Chief Executive Officer of the Company stated that the Company’s net interest income increased approximately $842,000, or 37.34%, during the quarter, compared to the same period in 2025. For the three months ending September 30, 2026, total interest income increased by approximately $851,000, or 28.93%, compared to the same period in 2025. Total interest expense increased approximately $9,000, or 1.31%, for the three-months ended September 30, 2026, compared to the same period in 2025. There was no provision for credit losses for the quarter ended September 30, 2026, compared to approximately $76,000 for the three-months ended September 30, 2025. For the quarter ending September 30, 2026, total non-interest income decreased approximately by $13,000, or (8.84%), while total non-interest expense increased approximately by $130,000, or 6.28%, compared to the same three-month period in 2025. The decrease in non-interest income was primarily attributable to a decrease in miscellaneous income of approximately $11,000, or (9.40%). The increase in non-interest expense was primarily attributable to increases in other operating expenses of approximately $85,000, or 37.12%, and salaries and benefits of approximately $69,000, or 5.16%, offset in part by a decrease in professional service expenses of approximately $27,000, or (12.80%).
        
The Company’s total assets at September 30, 2026 were $132.3 million, compared to $131.8 million at June 30, 2026. Total stockholders’ equity was approximately $18.4 million at September 30, 2026, or 13.89% of total assets, compared to approximately $18.4 million at June 30, 2026, or approximately 13.97% of total assets.

The Bank has four offices located in Gadsden, Albertville, Guntersville, and Centre, Alabama and a loan production office located in Birmingham, AL. The stock of The Southern Banc Company, Inc. trades on the OTC Basic Market under the symbol “SRNN”.

Certain statements in this release contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, which statements can generally be identified by the use of forward-looking terminology, such as “may,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “target,” “plan,” “project,” “continue,” or the negatives thereof, or other variations thereon or similar terminology, and are made on the basis of management’s plans and current analyses of the Company, its business and the industry as a whole. These forward-looking statements are subject to risks and uncertainties, including, but not limited to, economic conditions, competition, interest rate sensitivity and exposure to regulatory and legislative changes. The above factors, in some cases, have affected, and in the future could affect the Company’s financial performance and could cause actual results to differ materially from those expressed or implied in such forward-looking statements, even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized.

THE SOUTHERN BANC COMPANY, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL CONDITION (Dollar Amounts in Thousands)
		September 30,				June 30,
		2026				2026
		Unaudited				Audited
ASSETS
CASH AND CASH EQUIVALENTS	$	9,396			$	19,184
SECURITIES AVAILABLE FOR SALE, at fair value		43,262				43,424
FEDERAL HOME LOAN BANK (FHLB) STOCK		133				133
LOANS RECEIVABLE, net of allowance for loan losses of $2,032 and $1,715		75,379				65,358
PREMISES AND EQUIPMENT, net		1,147				1,148
ACCRUED INTEREST AND DIVIDENDS RECEIVABLE		1,270				1,105
PREPAID EXPENSES AND OTHER ASSETS		1,738				1,413
TOTAL ASSETS	$	132,325			$	131,765
LIABILITIES
DEPOSITS	$	103,117			$	104,341
FHLB ADVANCES AND OTHER BORROWED MONEY		–				–
OTHER LIABILITIES		10,833				9,012
TOTAL LIABILITIES		113,950				113,353
STOCKHOLDERS’ EQUITY:
Preferred stock, par value $.01 per share 500,000 shares authorized; no shares issued and outstanding		–				–
Common stock, par value $.01 per share, 3,500,000 authorized, 1,454,750 shares issued		15				15
Additional paid-in capital		13,950				13,951
Shares held in trust, 45,911 at cost		(787	)			(787	)
Retained earnings		16,977				16,215
Treasury stock, at cost, 648,664 shares		(8,825	)			(8,825	)
Accumulated other comprehensive (loss) income		(2,955	)			(2,157	)
TOTAL STOCKHOLDERS’ EQUITY		18,375				18,412
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	132,325			$	131,765

                                

THE SOUTHERN BANC COMPANY, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Dollar Amounts in Thousands, except per share data)
		Three Months Ended
		September 30,
		2026			2025
		(Unaudited)			(Unaudited)
INTEREST INCOME:
Interest and fees on loans	$	3,337		$	2,431
Interest and dividends on securities		313			239
Other interest income		143			272
Total interest income		3,793			2,942
INTEREST EXPENSE:
Interest on deposits		696			687
Interest on borrowings		–			–
Total interest expense		696			687
Net interest income before provision for loan losses		3,097			2,255
Provision for loan losses		–			76
Net interest income after provision for loan losses		3,097			2,179
NON-INTEREST INCOME:
Fees and other non-interest income		28			30
Net gain on sale of securities		–			–
Miscellaneous income		106			117
Total non-interest income		134			147
NON-INTEREST EXPENSE:
Salaries and employee benefits		1,406			1,337
Office building and equipment expenses		102			98
Professional services expense		184			211
Data processing expense		195			196
Other operating expense		314			229
Total non-interest expense		2,201			2,071
Income before income tax expense		1,030			255
INCOME TAX EXPENSE		268			67
Net income	$	762		$	188
INCOME PER SHARE:
Basic	$	1.00		$	0.25
Diluted		0.99			0.25
DIVIDENDS DECLARED PER SHARE	$	–		$	–
AVERAGE SHARES OUTSTANDING:
Basic		760,175			762,005
Diluted		766,439			765,285

Contact:
Gates Little                
(256) 543-3860

• RemIND data show clinically meaningful responses through Week 52 across three most prevalent CIndU subtypes, including after switching from placebo at Week 24¹
• Twice as many Rhapsido-treated patients achieved a treatment response by Week 1 in SD and ColdU vs placebo
• Rhapsido was well tolerated through Week 52, with an overall safety profile consistent with approved indications¹
• Additional regulatory submissions for CIndU planned based on these data

Basel, November 12, 2026 – Novartis today announced 52-week results from the Phase III RemIND program evaluating Rhapsido^®  (remibrutinib) in chronic inducible urticaria (CIndU). In the long-term analysis from the RemIND study, Rhapsido 25 mg twice daily showed early and sustained efficacy through Week 52 in patients across the three most prevalent CIndU subtypes: symptomatic dermographism (SD), cold urticaria (ColdU) and cholinergic urticaria (CholU).¹ The data will be presented as a late-breaking abstract at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting 2026.

“For people living with chronic inducible urticaria, everyday triggers like cold air, heat or even light scratching on the skin can lead to sudden, painful itching and swelling that can interfere with daily life,” said Giselle Mosnaim, MD, MS, allergist and immunologist at Endeavor Health and lead RemIND investigator. “This research is an important step toward finding treatment options that can provide lasting relief and help patients better manage their condition.”

RemIND is the largest Phase III clinical program conducted in CIndU.^1-5 Patients initially randomized to Rhapsido showed sustained efficacy through Week 52, with symptom improvements maintained throughout the treatment period.¹ After patients initially randomized to placebo switched to Rhapsido at Week 24, their response rates at Week 52 were similar to those observed in patients initially randomized to Rhapsido.¹

Complete or partial response rates on subtype-specific provocation tests were 41.8% with Rhapsido versus 19.2% with placebo in SD and 67.4% versus 28.9% in ColdU at Week 1, and 65.2% versus 45.6% in CholU at Week 2. At Week 52, complete or partial response rates were 46.8%, 83.3% and 58.2% in patients initially randomized to Rhapsido and 47.7%, 88.9% and 69.8% in patients who switched from placebo to Rhapsido at Week 24 in the SD, ColdU and CholU cohorts, respectively.¹

The 52-week RemIND results extend the safety evidence for Rhapsido in CIndU. Its safety profile through 52 weeks was consistent with previous studies and established experience in CSU.¹

“The RemIND program has generated the most comprehensive Phase III evidence to date in chronic inducible urticaria,” said Angelika Jahreis, Global Head, Immunology Development, Novartis. “These long-term data further strengthen the clinical profile of Rhapsido and underscore our commitment to advancing innovative treatment options for patients living with chronic urticaria. They will help support ongoing efforts to bring Rhapsido to more patients worldwide.”

About Chronic Inducible Urticaria (CIndU) 

CIndU affects an estimated 0.5 percent of the population, or 29 million people worldwide,^6,7 and differs from CSU, which has no specific triggers.⁸ It significantly burdens daily life, with many patients trying multiple antihistamines without adequate relief.⁹ The most prevalent subtype, symptomatic dermographism, causes itchy hives after skin friction or light scratching; hives appear within 5 minutes and usually last 30 minutes.¹⁰ Cold urticaria causes wheals or angioedema within minutes of cold exposure, usually in exposed areas, while cholinergic urticaria causes small, punctate hives after active or passive body heating, including exercise, strong emotions or hot-water bathing.¹⁰

About Rhapsido^®  (remibrutinib)

Rhapsido®  (remibrutinib) is a highly selective, oral Bruton’s tyrosine kinase (BTK) inhibitor that blocks the BTK pathway involved in immune-cell signaling and inflammation. Under the brand name Rhapsido, it is approved for chronic spontaneous urticaria (CSU) among other countries in the EU, US, CN and JP, and for symptomatic dermographism (SD), the most prevalent form of chronic inducible urticaria (CIndU), in the US.² Remibrutinib continues to be studied in other immune-mediated conditions, including hidradenitis suppurativa (HS), food allergy, chronic pruritus of unknown origin and papulopustular rosacea as well as multiple sclerosis (MS).

About the RemIND trial 

The RemIND trial (NCT05976243) is a global Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy, safety, and tolerability of Rhapsido in adults with CIndU inadequately controlled by H1-antihistamines. The RemIND trial enrolled 362 patients with CIndU whose symptoms remained inadequately controlled despite treatment with second-generation H1 antihistamines.^1,2 The primary endpoint of RemIND is the proportion of complete responders at Week 12 assessed through provocation tests specific to three CIndU subtypes. The secondary endpoints were change from baseline to the same endpoints at weeks 2 and 12; and the proportion of participants with complete response at weeks 2 and 24.^1,2 Data from RemIND supported the FDA approval of Rhapsido for the treatment of SD. The full data set will support additional regulatory submissions. ²

About Novartis Immunology

At Novartis, we’re advancing bold science with the goal of bringing relief and a renewed sense of hope to people living with autoimmune and other immune-mediated diseases. Building on our legacy of first-in-class innovation across rheumatology, dermatology and allergy, and a diverse industry-leading pipeline, we’re committed to shaping what’s next in Immunology.

Disclaimer

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide.

Reimagine medicine with us: Visit us at www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.

References

1. Giménez-Arnau AM, Ensina LF, Ferrucci SM, et al. Remibrutinib showed sustained efficacy and favorable safety profile through week 52 in chronic inducible urticaria. Presented as a late-breaker abstract at ACAAI 2026; November 12-16, 2026; Phoenix, AZ.
2. Rhapsido^® (remibrutinib) Prescribing Information. Novartis Pharmaceuticals Corp.
3. Finn AF Jr, Kaplan AP, Fretwell R, Qu R, Long J. A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol. 1999;104(5):1071-1078. doi:10.1016/s0091-6749(99)70091-6
4. ClinicalTrials.gov. NCT05030311. A Phase 3 study of efficacy and safety of remibrutinib in the treatment of CSU in adults inadequately controlled by H1 antihistamines (REMIX-1). Available from: https://clinicaltrials.gov/study/NCT05030311. Accessed October 7, 2026.
5. ClinicalTrials.gov. NCT05032157. A Phase 3 study of efficacy and safety of remibrutinib in the treatment of CSU in adults inadequately controlled by H1-antihistamines (REMIX-2). Available from: https://clinicaltrials.gov/study/NCT05032157. Accessed October 7, 2026.
6. Maurer M, et al. How to approach Chronic Inducible Urticaria, J Allergy Clin Immunol., 2018;6(4):1119-1130
7. World Population Prospects, Department of Economic and Social Affairs Population Division, United Nations. Available from: https://population.un.org/wpp/downloads?folder=Standard%20Projections&group=Population. Accessed, February 2026
8. Zuberbier et al. The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis and management of urticaria. Allergy, 2022;77(3):734–766
9. M Kern B, et al. Physician estimation of the prevalence and clinical impact of chronic urticaria: results of the global, multicenter UCARE CU-PAPER study. Frontiers in allergy, 2026, volume 6:1732893
10. Pozderac I, et al. Chronic inducible urticaria: classification and prominent features of physical and non-physical types. Acta Dermatovenerol Alp Pannonica Adriat. 2020;29(3):141–8

# # #

Novartis Media Relations E-mail: media.relations@novartis.com

Novartis Investor Relations Central investor relations line: +41 61 324 7944 E-mail: investor.relations@novartis.com

12 November 2026

REVEILLE RESOURCES PLC

(“Reveille”, or the “Company”)

Exercise of Warrants

Total Voting Rights

Reveille [AQSE: REV; OTCID: RVREF], a uranium exploration and development company with a primary focus on Italy’s largest uranium deposits, announces that it has received notice for the exercise of warrants in respect of 1,000,000 new ordinary shares of 1 pence each in the capital of the Company (“Ordinary Shares”) at an exercise price of 10 pence per share, raising gross proceeds of £100,000 for the Company (the “Warrant Shares”).

Admission to Trading and Total Voting Rights

Application will be made for the Warrant Shares to be admitted to trading on the Aquis Growth Market (“Admission”). It is anticipated that Admission will occur on or around 19 November 2026.

From Admission, the Company’s issued ordinary share capital will comprise of 84,755,465 Ordinary Shares, with one voting right per Ordinary Share. The Company does not hold any Ordinary Shares in Treasury. Therefore, from Admission, the total number of Ordinary Shares and voting rights in the Company will be 84,755,465.

From Admission, the above figure may be used by shareholders in the Company as the denominator for the calculations to determine if they are required to notify their interest in, or a change to their interest in the share capital of the Company, under the FCA’s Disclosure Guidance and Transparency Rules.

– ENDS –

For more information, please visit: www.reveille-resources.com or contact the following:

Reveille Resources Plc Ippolito Ingo Cattaneo, Executive Director	info@reveille-resources.com
Allenby Capital Limited, Aquis Corporate Advisor Nick Harriss / Ashur Joseph / Nick Naylor	Tel: +44 (0) 20 3328 5658
Community, Financial PR Italy Pasquo Cicchini / Virginia Giussani	Tel. +39 02 89404231

Notes to Editors

Reveille Resources plc (AQSE: REV; OTCID: RVREF) is a UK natural resources exploration and development company with a primary focus on Italy, where it is advancing the exploration and development of the country’s largest historic uranium deposits.

Through its Italian subsidiary, Futuro Energetico Italiano S.r.l, the Company has submitted exploration-licence applications in respect of the Novazza and Val Vedello uranium projects in northern Italy, each of which is subject to the applicable environmental-assessment process. The projects were historically explored and developed by AGIP Nucleare S.p.A. and its operating subsidiary, SOMIREN, both part of the ENI group, during Italy’s national nuclear programme between 1959 and 1983. This work included more than 87,000 metres of historical drilling and approximately 17 kilometres of underground development.

Reveille’s strategy is to identify and advance uranium projects that have benefited from substantial historical exploration and technical work, but where value has yet to be fully realised due to geopolitical, technological, financial or historical factors. By applying modern exploration techniques and internationally recognised reporting standards, the Company intends to verify historical data, advance exploration and work towards the delineation of mineral resources in accordance with internationally recognised reporting standards.

While Italy remains the Company’s principal area of focus, Reveille will selectively evaluate additional uranium opportunities elsewhere in Europe and in other Western jurisdictions where similar value creation opportunities exist. The Company is committed to advancing its projects responsibly, working closely with local communities, regulators and other stakeholders to ensure that exploration activities are undertaken to the highest environmental, technical and governance standards.

• 21 companies named 2026 Suppliers of the Year; in addition, 40 other companies recognized for standout performance
• More than 1,000 supplier representatives convened at the Stellantis Global Supplier Conference & Awards
• Conference highlighted product strategy, technology, design, quality and value creation, building on stronger supplier relationships to support FaSTLAne 2030

DETROIT, November 12, 2026 – Stellantis recognized 61 of its top-performing suppliers from around the world on Nov. 10 at its sixth annual Global Supplier Conference & Awards in Detroit. The honorees were recognized for exceptional performance, innovation and commitment to supporting Stellantis’ strategic priorities and delivering value to customers worldwide.

“Delivering on our strategy requires us to move faster, innovate smarter and execute with excellence. Our suppliers are essential partners in this journey, helping us bring great products to market, strengthen our competitiveness and create greater value for our customers,” said Antonio Filosa, Stellantis Chief Executive Officer. “Congratulations to all this year’s award winners, and thank you to our global supplier community for your partnership and continued commitment.”

The event, held at Detroit’s historic Masonic Temple, brought together more than 1,000 supplier representatives and members of the Stellantis Leadership Team for strategic dialogue and recognition.

Throughout the conference, Stellantis leaders highlighted key priorities for the Company’s future success, including program launch execution, emerging technologies, early supplier engagement in design, and continued improvement in quality performance. Leaders emphasized that strong supplier relationships and close collaboration will be essential to accelerating execution, strengthening competitiveness, and delivering FaSTLAne 2030.

“Strong supplier partnerships are built on trust, performance and continuous improvement,” said Monica Genovese, Chief Purchasing Officer, Stellantis, who hosted the event. “This year’s honorees distinguished themselves through their ability to deliver quality, innovation and value in a dynamic environment. Their performance strengthens our competitiveness and helps us create better outcomes for our customers.”

Stellantis leaders also outlined the Company’s product and technology strategies, quality transformation and global growth opportunities, emphasizing supplier collaboration as critical to accelerating execution and strengthening competitiveness.

With Detroit serving as the backdrop for this year’s event, the gathering underscored the region’s enduring significance to the automotive industry and its longstanding connection to Stellantis and the Chrysler, Dodge, Jeep_® and Ram brands. A dedicated presentation on Jeep brand strategy further highlighted how suppliers contribute to the customer experience and the brand’s success.

The awards recognize exceptional supplier achievements across Stellantis’ global regions and key areas of the business, including direct and indirect materials, quality, innovation, program management, corporate social responsibility, carbon reduction and value creation.

A global, cross-functional Stellantis team selected the 2026 honorees based on quality, delivery, innovation, operational and financial performance, corporate social responsibility, commercial competitiveness and support for shared business objectives.

2026 Stellantis Supplier of the Year Award Winners

AE Corp
Alpine
Alten
Arcese DP World
Benteler
Financière SNOP Dunois
Flex-N-Gate
Hilite
Infineon
Luxshare
Michelin
Metivo
MOBIS
MST Steel
OP Mobility
Petronas
Prime Wheel
Tapfin
Tianma
Tiberina
Valeo

Additional Suppliers Recognized in the Supplier of the Year Categories

Acciona
Adient
Aisin
APL
APG
Aumovio
Autoneum Holding AG
BASF
Brembo
Brose
CATL
CBWEE
Constellation
Desay
DN Automotive
ENGIE
Gestamp
GFX
Graphicient
Kalyani
Kerry Logistics
Magna
Mann+Hummel
Metaplast
Oakley
Orafol
Pirelli
Rediion
Sanai
Sansera Engineering
Sigit
Simoldes
Solstice
Sona Comstar
Sylvan
TomTom
Trebotti
Usiminas
VMAX
Voestalpine

# # #

About Stellantis

Stellantis (NYSE: STLA / Euronext Milan: STLAM / Euronext Paris: STLAP) is a leading global automaker, dedicated to giving its customers the freedom to choose the way they move, embracing the latest technologies and creating value for all its stakeholders. Its unique portfolio of iconic and innovative brands includes Abarth, Alfa Romeo, Chrysler, Citroën, Dodge, DS Automobiles, FIAT, Jeep_®, Lancia, Maserati, Opel, Peugeot, Ram, Vauxhall, Free2move and Leasys. For more information, visit Stellantis.com.

	@Stellantis		Stellantis		Stellantis		Stellantis
For more information, contact: Fernão SILVEIRA +1 947 252 3969 – fernao.silveira@stellantis.com Bashar CHOLAGH +1 248 425 4497 – bashar.cholagh@stellantis.com communications@stellantis.com www.stellantis.com

KUALA LUMPUR, Malaysia, Nov. 12, 2026 (GLOBE NEWSWIRE) — Treasure Global Inc. (NASDAQ: TGL) (“Treasure Global” or the “Company”), a Southeast Asia–anchored technology company focused on AI-powered enterprise solutions and digital transformation, today announced that it will effect a 1-for-24 reverse stock split (“Reverse Stock Split”) of its common stock, par value USD 0.00001 per share (“Common Stock”). Treasure Global’s Common Stock will continue to trade on the Nasdaq Capital Market (“Nasdaq”) under the existing ticker symbol “TGL” and will begin trading on a split-adjusted basis when the market opens on 16 November 2026. The new CUSIP number for the Common Stock following the Reverse Stock Split will be 89458T502.

The Reverse Stock Split is intended to increase the per-share trading price of the Company’s Common Stock to assist in regaining compliance with the Nasdaq minimum bid price requirement of USD 1.00 per share. There can be no assurance that the Company will maintain long-term compliance with Nasdaq listing requirements.

On November 5, 2026, the Company’s stockholders approved a proposal to authorize a reverse stock split of the Common Stock at a ratio within the range of 1-for-2 and 1-for-50 with the authority delegated to the Board of the Directors of the Company, to determine the exact reverse split ratio and when to file the Certificate of Amendment with the Secretary of State of the State of Delaware. On 9 November 2026, the Company filed a Certificate of Amendment to its Certificate of Incorporation to effect the Reverse Stock Split at the ratio of 1-for-24.

The 1-for-24 Reverse Stock Split will automatically combine and convert twenty-four (24) current shares of the Common Stock into one (1) issued and outstanding new share of Common Stock. Proportional adjustments also will be made to shares underlying outstanding equity awards, warrants, and convertible notes, as well as to the number of shares issued and issuable under the Company’s stock incentive plans and certain existing agreements. The Reverse Stock Split will not change the par value of the Common Stock nor the authorized number of shares of Common Stock, preferred stock, or any series of preferred stock. The Reverse Stock Split will also proportionally reduce the Company’s outstanding shares of Common Stock from 22,005,674 shares to approximately 916,903 shares.

No fractional shares will be issued in connection with the Reverse Stock Split. All fractional shares will be rounded up to the next whole share. The Reverse Stock Split will affect all stockholders uniformly and will not alter any stockholder’s percentage interest in the Company’s equity.

The Company’s transfer agent, Vstock Transfer, LLC, will serve as the agent for the Reverse Stock Split. Registered stockholders holding pre-split shares of the Common Stock electronically in book-entry form are not required to take any action to receive post-split shares. Stockholders owning shares via a broker, bank, trust, or other nominee will have their positions automatically adjusted to reflect the Reverse Stock Split and will not be required to take any action in connection with the Reverse Stock Split.

About Treasure Global:
Treasure Global is a Malaysia-based technology solutions provider specializing in innovative platforms that drive digital transformation in retail and services. The Company’s flagship product is the ZCITY Super App, which integrates e-payment solutions with customer loyalty rewards to create a seamless online-to-offline user experience. As of March 31, 2026, ZCITY has attracted 2.71 million registered users, positioning Treasure Global as a key player in Malaysia’s digital economy. Treasure Global continuously leverages cutting-edge technologies, including artificial intelligence and data analytics, to enhance its platform’s capabilities across e-commerce, fintech, and other verticals.

Visit treasureglobal.org for more information.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable U.S. federal securities laws. Forward-looking statements in this release include, among other matters, the anticipated completion and timing of the private placement, the issuance of the Company’s common stock, the intended use and potential benefits of the proceeds, and the Company’s future business and growth initiatives.

Factors that could cause actual results to differ materially include the satisfaction of closing conditions, applicable regulatory requirements, changes in market conditions, the Company’s ability to execute its business strategy and other risks described in the Company’s filings with the U.S. Securities and Exchange Commission.

The forward-looking statements contained in this release speak only as of the date hereof. The Company assumes no obligation to update or revise any forward-looking statements except as required by applicable law.

CONTACT
Investor and media contact:
Investor Relations Team
Treasure Global
ir_us@treasureglobal.org

ATHENS, Greece, Nov. 12, 2026 (GLOBE NEWSWIRE) — TOP Ships Inc. (the “Company” or “TOP Ships”) (NYSE American: TOPS), an international owner and operator of modern, fuel-efficient “ECO” tanker vessels, announced today that it has entered into an agreement with Rubico Inc., a related party, to sell 100% of the issued and outstanding shares of two Marshall Islands companies (the “SPVs”), each of which is party to a shipbuilding contract with Guangzhou Shipyard International Company Limited and China Shipbuilding Trading Co., Ltd. for the construction of a 47,499 dwt chemical/product oil carrier (the “Newbuilding MR Tankers”). The Newbuilding MR Tankers are scheduled for delivery in the fourth quarter of 2028 and the fourth quarter of 2029, respectively.

The aggregate selling price for 100% of the shares of the SPVs is approximately $14.5 million, payable at closing in cash or, at Rubico Inc.’s election, in whole or in part in Rubico Inc.’s Series G Perpetual Convertible Preferred Shares. The transaction is expected to close by March 31, 2027, subject to customary closing conditions.

The sale was approved by a special committee composed of independent and disinterested members of the Company’s board of directors, which obtained a fairness opinion with respect to the consideration to be received to sell the SPVs from an independent financial advisor.

About the Company

TOP Ships Inc. is an international owner and operator of ocean-going vessels focusing on modern, fuel-efficient eco tanker vessels transporting crude oil, petroleum products (clean and dirty) and bulk liquid chemicals. The Company’s tanker operating fleet has a total capacity of 857,000 dwt and consists of one 50,000 dwt product/chemical tanker, one 157,000 dwt Suezmax tanker, two 300,000 dwt VLCCs and, through a joint venture, 50% interests in two 50,000 dwt product tankers. The Company has entered into newbuilding contracts for ten 50,000 dwt MR newbuilding tankers scheduled for delivery from the second quarter of 2028 through the fourth quarter of 2029, two of which it has agreed to sell. In addition, the Company has entered into a share purchase agreement to acquire four shipowning companies that have entered into newbuilding contracts for four high-specification 50,000 dwt MR newbuilding tankers scheduled for delivery from the second quarter of 2029 through the first quarter of 2030, with closing being subject to customary closing conditions and the successful conclusion of the Financings by the Seller. The Company also owns the megayacht M/Y Para Bellvm, which it has announced its intention to divest. The Company is incorporated under the laws of the Republic of the Marshall Islands and has executive offices in Athens, Greece. Its common shares trade on the NYSE American under the symbol “TOPS”. For more information about TOP Ships Inc., visit its website: www.topships.org.

For further information please contact:

Alexandros Tsirikos

Chief Financial Officer

TOP Ships Inc.

Tel: +30 210 812 8107

Email: atsirikos@topships.org

Forward-Looking Statements

Matters discussed in this press release may constitute forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides safe harbor protections for forward-looking statements in order to encourage companies to provide prospective information about their business. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts, including statements regarding the sale of two newbuilding tankers and its expected closing, the expected delivery of our newbuilding vessels, the expected closing of the share purchase agreement to acquire four shipowning companies and our intention to divest the megayacht M/Y Para Bellvm.

The Company desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbor legislation. The words “believe,” “anticipate,” “intends,” “estimate,” “forecast,” “project,” “plan,” “potential,” “may,” “should,” “expect”, “pending” and similar expressions identify forward-looking statements. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, our management’s examination of historical operating trends, data contained in our records and other data available from third parties. Although we believe that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond our control, we cannot assure you that we will achieve or accomplish these expectations, beliefs or projections. Please see the Company’s filings with the Securities and Exchange Commission for a more complete discussion of these and other risks and uncertainties. The information set forth herein speaks only as of the date hereof, and the Company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this communication.

To Bond’s knowledge, this is the first major city in the world to fund a personal security service for all of its residents, now with local schools presenting Bond to students ages 8 to 18

Bond is in discussions with approximately 20 cities across France and Israel and is launching a campaign for cities in the United States as it builds its business-to-government-to-consumer model into a growth engine

NEW YORK, Nov. 12, 2026 (GLOBE NEWSWIRE) — Our Bond, Inc. (“Bond”) (NASDAQ: OBAI), the creator of the world’s first AI-powered Preventative Personal Security platform adopted by leading multinational companies, today shared key metrics from the citywide program run by the municipality that funds Bond for all of its approximately 270,000 residents, which Bond announced in June. To Bond’s knowledge, it is the first major city in the world to fund a personal security service for all of its residents.

Among residents introduced to the service, Bond has consistently seen approximately 60% choose to enroll, compared with an industry average of approximately 5%, and resident members report high overall satisfaction. The city has now extended the program to local schools, which have begun presenting Bond to students ages 8 to 18, reaching younger residents and their families.

“We believe we are witnessing the emergence of a new category of municipal services, city-sponsored preventative personal security,” said Doron Kempel, Founder and Chief Executive Officer of Bond. “When residents understand what Bond offers, most of them choose to use it, with about 60% of those introduced to the service enrolling, roughly 12 times the industry average. To our knowledge, no other major city has funded personal security for its entire population, and with schools now presenting Bond to students, the program continues to grow. We are now working to turn this experience into a scalable municipal offering, with discussions underway with cities across France and Israel and the start of our outreach to U.S. cities. We believe our business-to-government-to-consumer model is becoming one of Bond’s most important growth engines.”

B2G2C as a Growth Engine for Bond

Personal security has traditionally been purchased by individuals, families or employers. Under Bond’s business-to-government-to-consumer (B2G2C) model, a city funds access for its residents as a public benefit and introduces the service through local institutions such as schools, which allows Bond to reach an entire population through a single relationship with the city. Adoption is also supported by Bond’s privacy-preserving design. An independent study by a Big Four Accounting and Consulting firm found that Bond’s guarantee of privacy helps drive high adoption rates. Bond is in discussions with approximately 20 cities across France and Israel and is launching a campaign to bring Bond to cities in the United States.

Bond’s AI-powered platform combines advanced technology with trained Personal Security Agents who are available 24/7 and respond by video within seconds, to help identify potential threats, provide real-time guidance, de-escalate situations and coordinate with law enforcement and emergency responders when necessary. Rather than relying solely on a panic button or emergency response after an incident occurs, Bond is designed to help prevent situations from escalating in the first place.

About Bond
Bond is an international company headquartered in New York City — with command centers around the world — that is redefining personal security through its AI-powered Preventative Personal Security platform. The company has invested more than $100 million to date in its technology, operations, and global expansion.

Bond offers personal security to more people than any other company globally. Bond is trusted by leading corporations, cities, and universities, and has already supported more than 1.4 million security service requests, including over 10,000 emergencies and life-saving interventions. Bond operates in 28 countries and growing, positioning itself as a new global standard for personal security and peace of mind. Additional information about the Company is available at: www.ourbond.com.

Forward-Looking Statement

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance, or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including the risks discussed under the heading “Risk Factors” in our most recent Registration Statement on Form S-1, under the caption “Item 1A. Risk Factors” in Part I of our most recent Annual Report on Form 10-K, or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of our Quarterly Reports on Form 10-Q and in our other filings with the SEC, copies of which are available on the SEC’s website at www.sec.gov. Our Bond, Inc. undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise that occur after the date of this release, except as required by law.

Contact:
Crescendo Communications, LLC
212-671-1020
OBAI@crescendo-ir.com

To Bond’s knowledge, this is the first major city in the world to fund a personal security service for all of its residents, now with local schools presenting Bond to students ages 8 to 18

Bond is in discussions with approximately 20 cities across France and Israel and is launching a campaign for cities in the United States as it builds its business-to-government-to-consumer model into a growth engine

NEW YORK, Nov. 12, 2026 (GLOBE NEWSWIRE) — Our Bond, Inc. (“Bond”) (NASDAQ: OBAI), the creator of the world’s first AI-powered Preventative Personal Security platform adopted by leading multinational companies, today shared key metrics from the citywide program run by the municipality that funds Bond for all of its approximately 270,000 residents, which Bond announced in June. To Bond’s knowledge, it is the first major city in the world to fund a personal security service for all of its residents.

Among residents introduced to the service, Bond has consistently seen approximately 60% choose to enroll, compared with an industry average of approximately 5%, and resident members report high overall satisfaction. The city has now extended the program to local schools, which have begun presenting Bond to students ages 8 to 18, reaching younger residents and their families.

“We believe we are witnessing the emergence of a new category of municipal services, city-sponsored preventative personal security,” said Doron Kempel, Founder and Chief Executive Officer of Bond. “When residents understand what Bond offers, most of them choose to use it, with about 60% of those introduced to the service enrolling, roughly 12 times the industry average. To our knowledge, no other major city has funded personal security for its entire population, and with schools now presenting Bond to students, the program continues to grow. We are now working to turn this experience into a scalable municipal offering, with discussions underway with cities across France and Israel and the start of our outreach to U.S. cities. We believe our business-to-government-to-consumer model is becoming one of Bond’s most important growth engines.”

B2G2C as a Growth Engine for Bond

Personal security has traditionally been purchased by individuals, families or employers. Under Bond’s business-to-government-to-consumer (B2G2C) model, a city funds access for its residents as a public benefit and introduces the service through local institutions such as schools, which allows Bond to reach an entire population through a single relationship with the city. Adoption is also supported by Bond’s privacy-preserving design. An independent study by a Big Four Accounting and Consulting firm found that Bond’s guarantee of privacy helps drive high adoption rates. Bond is in discussions with approximately 20 cities across France and Israel and is launching a campaign to bring Bond to cities in the United States.

Bond’s AI-powered platform combines advanced technology with trained Personal Security Agents who are available 24/7 and respond by video within seconds, to help identify potential threats, provide real-time guidance, de-escalate situations and coordinate with law enforcement and emergency responders when necessary. Rather than relying solely on a panic button or emergency response after an incident occurs, Bond is designed to help prevent situations from escalating in the first place.

About Bond
Bond is an international company headquartered in New York City — with command centers around the world — that is redefining personal security through its AI-powered Preventative Personal Security platform. The company has invested more than $100 million to date in its technology, operations, and global expansion.

Bond offers personal security to more people than any other company globally. Bond is trusted by leading corporations, cities, and universities, and has already supported more than 1.4 million security service requests, including over 10,000 emergencies and life-saving interventions. Bond operates in 28 countries and growing, positioning itself as a new global standard for personal security and peace of mind. Additional information about the Company is available at: www.ourbond.com.

Forward-Looking Statement

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance, or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including the risks discussed under the heading “Risk Factors” in our most recent Registration Statement on Form S-1, under the caption “Item 1A. Risk Factors” in Part I of our most recent Annual Report on Form 10-K, or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of our Quarterly Reports on Form 10-Q and in our other filings with the SEC, copies of which are available on the SEC’s website at www.sec.gov. Our Bond, Inc. undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise that occur after the date of this release, except as required by law.

Contact:
Crescendo Communications, LLC
212-671-1020
OBAI@crescendo-ir.com

DECLARATION DU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL
ET DU NOMBRE TOTAL DE DROITS DE VOTE AU 31 OCTOBRE 2026

Article L. 233-8-II du Code de Commerce
Article 223-16 du Règlement général de l’AMF

Nombre d’actions composant le capital social	238 313 588
Nombre de droits de vote théoriques	255 208 634
Nombre de droits de vote exerçables	254 968 013

Cette déclaration est en ligne sur le site internet d’Elis www.elis.com

DISCLOSURE OF THE NUMBER OF SHARES FORMING THE CAPITAL
AND OF THE TOTAL NUMBER OF VOTING RIGHTS AS OF 31 OCTOBER 2026

Total number of shares	238,313,588
Theoretical number of voting rights	255,208,634
Number of exercisable voting rights	254,968,013

This disclosure is on Elis web site www.elis.com

Contacts

Nicolas Buron, Director of Investor Relations, Financing & Treasury
Phone: +33 1 75 49 98 30 – nicolas.buron@elis.com

Charline Lefaucheux, Investor Relations
Phone: +33 1 75 49 98 15 – charline.lefaucheux@elis.com

Attachment

• Disclosure of the number of shares forming the capital and of the total number of voting rights as of 31 10 2026

DECLARATION DU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL
ET DU NOMBRE TOTAL DE DROITS DE VOTE AU 31 OCTOBRE 2026

Article L. 233-8-II du Code de Commerce
Article 223-16 du Règlement général de l’AMF

Nombre d’actions composant le capital social	238 313 588
Nombre de droits de vote théoriques	255 208 634
Nombre de droits de vote exerçables	254 968 013

Cette déclaration est en ligne sur le site internet d’Elis www.elis.com

DISCLOSURE OF THE NUMBER OF SHARES FORMING THE CAPITAL
AND OF THE TOTAL NUMBER OF VOTING RIGHTS AS OF 31 OCTOBER 2026

Total number of shares	238,313,588
Theoretical number of voting rights	255,208,634
Number of exercisable voting rights	254,968,013

This disclosure is on Elis web site www.elis.com

Contacts

Nicolas Buron, Director of Investor Relations, Financing & Treasury
Phone: +33 1 75 49 98 30 – nicolas.buron@elis.com

Charline Lefaucheux, Investor Relations
Phone: +33 1 75 49 98 15 – charline.lefaucheux@elis.com

Attachment

• Disclosure of the number of shares forming the capital and of the total number of voting rights as of 31 10 2026